TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05468086

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VR Solace
Description: Participants will use the VR audio and visual head-mounted device. The device is a standalone VR headset. The device supports 3 degrees of freedom (3DOF) head tracking, has best-in-class optics, and a wide field-of-view.
Study: NCT06513793

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Roots and Shoots
Description: Four-week intervention involving a self-help guidebook to improve mental wellbeing.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Waiting list
Description: Four-week waiting list period involving treatment as usual.
Study: NCT04893590

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fatigue self-management SMS intervention
Description: Participants will set up an initial goal for the SMS intervention related to fatigue management, and prior to beginning the intervention they will be trained to use the SMS system. Participants will receive text messages each day, providing tips and techniques to help self-manage fatigue. Weekly the participants will be asked to provide feedback regarding their fatigue levels and their patient activation will be re-assessed at the halfway point of intervention.
Study: NCT05952219

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-379
Description: 2 tablet administration under fed condition

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-379
Description: 2 tablet administration under fed condition

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D759+D745+D029+D150
Description: 4 tablet co-administration under fed condition

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D759+D745+D029+D150
Description: 4 tablet co-administration under fed condition
Study: NCT04080115

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Attention Training Technique
Description: ATT will be administered through a customized Expiwell smartphone application that will be downloaded onto participants' cell phones at the first laboratory session (T2). For the purposes of the proposed study, participants need to complete the intervention once a day, for the six days between their lab sessions; signals will begin the day after their T2 session and they will be notified up to a maximum of five times per day to complete their daily session. The ATT sessions are comprised of three phases. The first is a 5-minute phase during which the participant is instructed to attend to specific sounds in the recording and disregard other sounds. The subsequent 5-minute phase includes instructions to rapidly switch their attention between sounds in the recording. The final phase is a dual attention task lasting 2 minutes wherein the participant is instructed to pay attention to multiple sounds in the recording at once. In total, each session of ATT lasts 12 minutes.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sham intervention control condition
Description: The sham control condition consists of the same 12 minutes of simultaneous sounds as the ATT technique, but will not include any verbal instruction, thus isolating the effects of intentional orientation of attention.
Study: NCT05170139

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Caffeine
Description: Participants will ingest a drink with 3mg/kg of body weight mixed with carbohydrates

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo drink
Description: Participants will ingest the exact same drink without caffeine
Study: NCT04848363

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Quadratus lumborum block
Description: QL block will be used for perioperative anesthesia. The blockade will be performed bilaterally by levobupivacaine (20ml) at concentration 0.25%.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Quadratus lumborum block
Description: QL block will be used for perioperative anesthesia. The blockade will be performed bilaterally by levobupivacaine (20ml) at concentration 0.25%.
Study: NCT05827146

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hepalatide
Description: Either the placebo or hepalatide (2.1 mg, 4.2 mg, or 6.3 mg) will be given for 4 consecutive weeks. s.c., once daily.
Study: NCT06168656

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile Application
Description: The mobile application will include the following features:~Direct Message Section: This section will allow expectant fathers to ask specialized questions directly to experts or specialists.~Forum Section: Expectant fathers can use this section to engage in discussions and connect with each other.~Education Section: This section is specifically designed to cater to the educational needs of expectant fathers.
Study: NCT05827146

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hepalatide
Description: Either the placebo or hepalatide (2.1 mg, 4.2 mg, or 6.3 mg) will be given for 4 consecutive weeks. s.c., once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hepalatide
Description: Either the placebo or hepalatide (2.1 mg, 4.2 mg, or 6.3 mg) will be given for 4 consecutive weeks. s.c., once daily.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Hepalatide Placebo
Description: Either the placebo or hepalatide (2.1 mg, 4.2 mg, or 6.3 mg) will be given for 4 consecutive weeks. s.c., once daily.
Study: NCT05207436

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin nasal spray
Description: Veteran participants will self-administer 40 IU of intranasal oxytocin 30 minutes before the start of each B-CBCT session.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Cognitive-Behavioral Conjoint Therapy
Description: Eight sessions of standardized B-CBCT, a manualized couple-based intervention for PTSD designed to simultaneously reduce PTSD and enhance relationship and functioning.
Study: NCT05762939

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Chatbot
Description: Participants in this condition were asked to use Fido, a Polish therapy chatbot, for two weeks. No minimal requirements of usage time were enforced, but participants had to fill in five engagement check surveys during the intervention period. Each survey had to be completed in less than 24 hours.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control (book)
Description: Participants in this condition were told to read selected chapters from a self-help book during the two-week intervention period. No minimal requirements of usage time were enforced, but participants had to fill in five engagement check surveys during the intervention period. Each survey had to be completed in less than 24 hours.
Study: NCT05078879

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin
Description: This is an open-label pilot study to evaluate the efficacy, safety, and tolerability of empagliflozin as a treatment for severe congenital neutropenia (SCN) in patients with glucose-6-phosphatase 3 (G6PC3) deficiency. Participants will be on a 12-month daily regimen of empagliflozin at a starting dose of 10 mg (phase A), which may be increased after 2 months to 25 mg (phase B). Evaluate the safety and efficacy of the biomarker response (the change in absolute neutrophil count \[ANC\] after one year of empagliflozin treatment relative to baseline ANC prior to drug treatment) in patients with G6PC3 deficiency.
Study: NCT05218122

Intervention type: OTHER
Intervention: cross-sectional study without intervention
Description: cross-sectional study without intervention

Intervention type: OTHER
Intervention: cross-sectional study without intervention
Description: cross-sectional study without intervention

Intervention type: OTHER
Intervention: cross-sectional study without intervention
Description: cross-sectional study without intervention
Study: NCT05313009

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sotorasib and Tarloxotinib
Description: Sotorasib 960 mg PO daily + tarloxotinib 150 mg/m2 IV weekly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sotorasib and Tarloxotinib
Description: Sotorasib 960 mg PO daily + tarloxotinib 150 mg/m2 IV weekly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sotorasib and Tarloxotinib
Description: Sotorasib 960 mg PO daily + tarloxotinib IV weekly at the combination RP2D (RP2Dc).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sotorasib and Tarloxotinib
Description: Sotorasib 960 mg PO daily + tarloxotinib IV weekly at the combination RP2D (RP2Dc).
Study: NCT05674526

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: WU-NK-101 - Dose Escalation
Description: WU-NK-101 administered on Days 1, 15, 30 and 44

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab - Dose Escalation
Description: Cetuximab 500mg/m2 administered on Days 29 and 43

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: WU-NK-101 - Cohort Expansion
Description: WU-NK-101 administered on Days 2 and 16

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cetuximab - Cohort Expansion
Description: Cetuximab 500mg/m2 administered on Days 1 and 15
Study: NCT05440799

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1819479
Description: BI 1819479

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: BI matching placebo
Description: BI matching placebo
Study: NCT05583747

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iTBS
Description: rTMS involves direct stimulation of cortical neurons using externally applied, powerful, focused magnetic field pulses. iTBS is a briefer form of patterned rTMS that has been shown to be effective against MDD, despite a stimulation period of 1-3 min rather than 30-40 min.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: iTBS
Description: rTMS involves direct stimulation of cortical neurons using externally applied, powerful, focused magnetic field pulses. iTBS is a briefer form of patterned rTMS that has been shown to be effective against MDD, despite a stimulation period of 1-3 min rather than 30-40 min.
Study: NCT05754827

Intervention type: DIAGNOSTIC_TEST
Intervention: RDW to platlet count ratio
Description: RDW to platlet ratio will be measured for all patients and results will be compared between groups

Intervention type: DIAGNOSTIC_TEST
Intervention: RDW to platlet count ratio
Description: RDW to platlet ratio will be measured for all patients and results will be compared between groups
Study: NCT06643247

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Drug
Description: 1) Valacyclovir Hydrochloride tablets, 0.3 g per dose, twice daily; 2) Mecobalamin tablets, 0.5 mg, three times daily. Taken continuously for 7 days.The affected skin is kept clean and protected to maintain lesion integrity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug
Description: 1) Valacyclovir Hydrochloride tablets, 0.3 g per dose, twice daily; 2) Mecobalamin tablets, 0.5 mg, three times daily. Taken continuously for 7 days.The affected skin is kept clean and protected to maintain lesion integrity.
Study: NCT05946876

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XH-S003 (A)
Description: IP: XH-S003 IP: XH-S003 Dose: 25 mg, 100 mg Dose Formulation: Capsule Route of Administration: Oral

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (B)
Description: Dose: 25 mg, 100 mg Dose Formulation: Capsule Route of Administration: Oral
Study: NCT05836662

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CrashCourse Concussion Education in Virtual Reality
Description: The TeachAids concussion education, including CrashCourse and Brain Fly-Through, will be shown in 3D (via a Virtual Reality headset). These educations are the exact same content as the 2D versions viewed on a laptop, but the modality (via a VR headset) is different.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CrashCourse Concussion Education in Virtual Reality
Description: The TeachAids concussion education, including CrashCourse and Brain Fly-Through, will be shown in 3D (via a Virtual Reality headset). These educations are the exact same content as the 2D versions viewed on a laptop, but the modality (via a VR headset) is different.
Study: NCT05819866

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leriglitazone
Description: Leriglitazone at a strength of 15 mg/ml. Once-daily dosing at an initial volume of 10 ml

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will match the study drug visually and by taste
Study: NCT05843630

Intervention type: DIAGNOSTIC_TEST
Intervention: without
Description: without

Intervention type: DIAGNOSTIC_TEST
Intervention: without
Description: without

Intervention type: DIAGNOSTIC_TEST
Intervention: without
Description: without
Study: NCT05401422

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: treatment
Description: types

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: treatment
Description: types

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: treatment
Description: types
Study: NCT05149079

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Cod protein hydrolysate
Description: Rest raw materials (RRM) from cod (Fjordlaks AS, Norway) are used for the hydrolysis production (Food Grade). Freshly minced RRM is treated wth enzymes optimized to generate bioactive hydrolysates using facilities and techniques approved for human consumption.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Whey protein powder, commercially available
Study: NCT06314906

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electroacupuncture
Description: Participants in this arm will undergo electroacupuncture sessions once daily from day 1 to day 4. Electrical stimulation will be administered for 30 minutes at alternating frequencies of 2/10Hz

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antiemetic Therapy
Description: Participants will receive oral olanzapine at a dose of 5 mg per day on days 1 through 4, along with NK1 receptor antagonist, 5HT3 receptor antagonist, and intravenous dexamethasone at a dose of 10 mg 30 minutes prior to chemotherapy on Day 1, followed by intravenous dexamethasone at a dose of 8 mg on days 2, 3, and 4 post-chemotherapy.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sham electroacupuncture
Description: Participants assigned to this arm will receive sham electroacupuncture sessions daily from day 1 to day 4, mirroring the schedule of the experimental group

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Antiemetic Therapy
Description: They will also receive the same antiemetic medications as the experimental group.
Study: NCT05419154

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Early pain dependent weight-bearing without immobilization
Description: Patients are advised to conduct pain-dependent full weight-bearing starting at the day of study inclusion. In case of severe swelling, a splint or below knee cast can be applied until the initial swelling subsides, but no longer than 14 days. Otherwise, no immobilization is applied. The use of crutches is allowed per the individual patients demands. The physiotherapists at the individual study centers are informed prior to study initiation and are briefed about each patient enrolled in the study. Each patient is handed an information sheet for their outpatient physiotherapist.
Study: NCT05348005

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ovira Transcutaneous Electrical Nerve Stimulation Unit
Description: TENS units have a wide application from treatment of chronic back pain, chronic abdominal pain, cancer pain, perioperative pain, and labor pain.19-24 TENS units have been shown to be well-tolerated with minimal side effects and have been successful in reducing pain as well as pain medication use in patients with primary dysmenorrhea, which excludes pathology such as endometriosis. 11-18 Certain TENS units have also been FDA approved for the general indication of pelvic pain.
Study: NCT04907487

Intervention type: DEVICE
Intervention: MRI
Description: MRI of routine care includes at least the following sequences:~* 3D T1 TFE (2 minutes)~* T2 TSE (2 minutes)~* 3D FLAIR (3 minutes)~The sequences added by the research lasting 25 minutes are:~* SWI QSM 1.0iso 8 echoes (10 minutes)~* SWI QSM 1.0iso 8 echoes CS 6 (7 minutes)~* SWI QSM 1.0iso 8 echoes CS 9 (5 minutes)~* SWI QSM 1.0iso 8 echoes CS 12 (3 minutes)

Intervention type: DEVICE
Intervention: MRI
Description: MRI of routine care includes at least the following sequences:~* 3D T1 TFE (2 minutes)~* T2 TSE (2 minutes)~* 3D FLAIR (3 minutes)~The sequences added by the research lasting 25 minutes are:~* SWI QSM 1.0iso 8 echoes (10 minutes)~* SWI QSM 1.0iso 8 echoes CS 6 (7 minutes)~* SWI QSM 1.0iso 8 echoes CS 9 (5 minutes)~* SWI QSM 1.0iso 8 echoes CS 12 (3 minutes)
Study: NCT05353569

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: OCT Device(s)
Description: Results from standard-of-care examinations will be compared to research-only examination(s) (OCT device(s)).

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: OCT Device(s)
Description: Results from standard-of-care examinations will be compared to research-only examination(s) (OCT device(s)).
Study: NCT06067529

Intervention type: DRUG
Intervention: hormone replacement therapy
Description: hormone replacement therapy
Study: NCT05665309

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 3D anatomical model of aneurysm
Description: Surgery prepared with 3D anatomical model of aneurysm
Study: NCT04716439

Intervention type: PROCEDURE
Intervention: Spine Surgery
Description: spine decompression and fixation
Study: NCT06014905

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyperpolarized carbon C 13 pyruvate
Description: Given Intravenously (IV)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Image (MRI)
Description: Imaging procedure

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Saline
Description: Given IV
Study: NCT05920850

Intervention type: OTHER
Group type: OTHER
Intervention: Educational Video about LDCT lung cancer screening
Description: A culturally tailored video that provides education about the process LDCT lung cancer screening

Intervention type: OTHER
Group type: OTHER
Intervention: A culturally tailored shared decision-making tool
Description: A culturally tailored shared decision-making tool that educates participants about the shared decision-making process

Intervention type: OTHER
Group type: OTHER
Intervention: Flip chart
Description: The use of a flip chart that reinforces the information provided in the video and shared decision-making tool

Intervention type: OTHER
Group type: OTHER
Intervention: Navigation support
Description: Navigation support for participants who express interest in LDCT and quitting smoking.
Study: NCT05782413

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mechanical vestibular stimulation
Description: Device produces mechanical vestibular stimulation. The child was placed in a sitting position on the swing and his hands grasping the ropes at the sides then the therapist stood behind him and begin pushing the platform in fast and jerky movements in back and front, side to side, and in spinning directions with the child trying to maintain his balance in all different directions.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The design exercise program
Description: A selected therapeutic exercises program was based on the principles of NDTBobath neurodevelopmental therapy, which is effective in controlling spasticity in children with cerebral palsy and improving motor function.~i. Preparation of structures and mobilizations of the scapula, shoulder joint, and chest according to the NDT-Bobath concept ii. Exercises to increase shoulder mobility and elbow joint extension. iii. Fine motor skill exercises, wrist, and hand

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The design exercise program
Description: A selected therapeutic exercises program was based on the principles of NDTBobath neurodevelopmental therapy, which is effective in controlling spasticity in children with cerebral palsy and improving motor function.~i. Preparation of structures and mobilizations of the scapula, shoulder joint, and chest according to the NDT-Bobath concept ii. Exercises to increase shoulder mobility and elbow joint extension. iii. Fine motor skill exercises, wrist, and hand
Study: NCT05165329

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: PEANUT OIT: Peanut Flour (50% peanut protein) that is prepared under food manufacturing regulations
Description: PROBIOTIC: The probiotic to be used is Lactobacillus rhamnosus GG, supplied as a freeze-dried powder. Probiotic will be prepared under strict Food Manufacturing Regulations. The daily dose of 2x10\^10 cfu will be packed individually in sachets. Participants will be instructed to mix one scoop of the probiotic in water at a temperature NOT exceeding 38 degrees Celsius. The probiotic must be stored at 4 degrees Celsius

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: PEANUT OIT: Peanut Flour (50% peanut protein) that is prepared under food manufacturing regulations
Description: PROBIOTIC PLACEBO: Probiotic Placebo is maltodextrin. The daily dose will be measured using a standardised scoop. Participants will be instructed to mix one scoop of the probiotic in water at a temperature NOT exceeding 38 degrees Celsius. The probiotic should be stored at 2-8 degrees Celsius.

Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: PEANUT PLACEBO: Peanut Placebo is maltodextrin powder with food colouring and peanut essence that has similar appearance, taste and smell to the active product.
Description: PROBIOTIC PLACEBO: Probiotic Placebo is maltodextrin. The daily dose will be measured using a standardised scoop. Participants will be instructed to mix one scoop of the probiotic in water at a temperature NOT exceeding 38 degrees Celsius. The probiotic should be stored at 2-8 degrees Celsius.
Study: NCT04739124

Intervention type: OTHER
Intervention: Follow-up questionnaires
Description: The patient normally follows the education program as usual but research specific data is collected:~* Biological sampling at the start and end of the education program (glycated hemoglobin).~* Retrieval of usage and glycemic balance data from the Libreview online platform (at one week, one month and three months of use)~* Iterative questionnaires allowing the study of factors of acceptance, appropriation and use (at the start of the study, at 4 weeks, at 12 weeks)

Intervention type: OTHER
Intervention: Follow-up questionnaires
Description: The patient normally follows the education program as usual but research specific data is collected:~* Biological sampling at the start and end of the education program (glycated hemoglobin).~* Retrieval of usage and glycemic balance data from the Libreview online platform (at one week, one month and three months of use)~* Iterative questionnaires allowing the study of factors of acceptance, appropriation and use (at the start of the study, at 4 weeks, at 12 weeks)

Intervention type: OTHER
Intervention: Interviews
Description: Semi-structured interviews will be carried out during the visits, either face-to-face or remotely.